Ticker brief
SRPT
last close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
5
authors 14d
5
crowd 14d
-0.1σ
No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.
Options inteloptions-surface reads · latest available day per source
| metric | reading | context |
|---|---|---|
| IV — ATM 30d | 72% cheap · 16 pctile own 1y | HV n/a |
| Skew — 25Δ RR 30d | -0.050 30 pctile own 1y | balanced vs own range |
Sentiment — last 14 days
daily mean sentiment, 2026-10-06 → 2026-10-14 · now +0.17 (−1 bearish … +1 bullish)
Who spoke5
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @PhotonCap | A | -0.73 | 1 | -0.15 |
| @commonsenseplay | C | -1.31 | 1 | +0.85 |
| @OzmosiHealth | C | · | 1 | +0.30 |
| @BiopharmIQ | B | · | 1 | +0.00 |
| @OracleNYSE | C | +0.83 | 1 | +0.20 |
Recent signals5of 5 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-10-14 | @OracleNYSE | +0.20 | FDA launched a rare-disease review overhaul seeking flexible approvals for small populations. | · | tweet ↗ |
| 2026-10-14 | @BiopharmIQ | +0.00 | Lists opening price moves and biotech news catalysts; output is capped at the first six tickers. | · | tweet ↗ |
| 2026-10-14 | @OzmosiHealth | +0.30 | Sarepta presented preclinical data showing robust knockdown of pathogenic RNA with SRP-1003. | · | tweet ↗ |
| 2026-10-12 | @commonsenseplay | +0.85 | Bought more SRPT ahead of November catalysts, with a $45 upside case. — Explicitly bought more and expects $45 if upcoming November readouts succeed. | · | tweet ↗ |
| 2026-10-06 | @PhotonCap | -0.15 | Relays Jim Cramer's characterization of Sarepta as very controversial. | · | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.